Publicacións nas que colabora con Emilia Cercenado Mansilla (45)

2023

  1. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis

    The Lancet Regional Health - Europe, Vol. 34

  2. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project)

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2291-2296

2022

  1. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

    International Journal of Antimicrobial Agents, Vol. 59, Núm. 1

  2. Emergence of methicillin resistance predates the clinical use of antibiotics

    Nature, Vol. 602, Núm. 7895, pp. 135-141

  3. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

    Microbiology spectrum, Vol. 10, Núm. 5, pp. e0292722

  4. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3163-3172

2021

  1. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2677-2699

  2. Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 6, pp. 1498-1510

  3. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 2, pp. 370-379

  4. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1631-1637

2020

  1. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

  2. WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 4

2019

  1. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study

    International Journal of Antimicrobial Agents, Vol. 53, Núm. 5, pp. 682-688

2018

  1. Serotypes and genotypes of S. pneumoniae isolates from adult invasive disease in Spain: A 5-year prospective surveillance after pediatric PCV13 licensure. The ODIN study

    Vaccine, Vol. 36, Núm. 52, pp. 7993-8000

2017

  1. Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436

2016

  1. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain

    Journal of Infection, Vol. 72, Núm. 2, pp. 152-160

2015

  1. Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain

    International Journal of Antimicrobial Agents, Vol. 46, Núm. 2, pp. 157-163

2014

  1. Inhibitor-resistant TEM- And OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates

    Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 7, pp. 3874-3881

2013

  1. Epidemiological and clinical complexity of amoxicillin-clavulanate- resistant Escherichia coli

    Journal of Clinical Microbiology, Vol. 51, Núm. 7, pp. 2414-2417

2012

  1. Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 8, pp. 4540-4543